BTKi Therapy for CLL: EHA 2023
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023

Released: July 28, 2023

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

  • CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
  • SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
  • CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
  • Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
  • BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL